- Alcobra (ADHD) will be able to start U.S. trials of its Metadoxine Extended Release (MDX) treatment for Attention Deficit Hyperactivity Disorder (ADHD), Fragile X Syndrome and other cognitive dysfunctions after the FDA approved the company's Investigational New Drug (IND) application for the treatment.
- Alcobra expects to soon start enrolling adult patients in a Phase III trial of MDX. (PR)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs